Price Cut, Generics Hit Pfizer’s Japanese Sales
This article was originally published in PharmAsia News
Pfizer’s Japanese pharma sales last year were hit not only by the regular biennial reimbursement price cut in April but also by stronger than expected generic competition.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.